A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if receiving sub-cutaneous injections of a
medication called abatacept causes regrowth of hair in people with alopecia areata.
Among patients with alopecia areata, patients with worse disease are unlikely to have
satisfactory outcomes with current therapies. Our hypothesis is that Abatacept will be
effective therapy in moderate to severe alopecia areata by blocking re-activation of a
special type of immunecell call a memory T-Cell (CD8+NKG2D+)thereby blocking the inflammatory
response underlying alopecia areata.